Faheem W Guirgis1, Scott Brakenridge, Selina Sutchu, Jay D Khadpe, Taylor Robinson, Richard Westenbarger, Stephen T Topp, Colleen J Kalynych, Jennifer Reynolds, Sunita Dodani, Frederick A Moore, Alan E Jones. 1. From the Department of Emergency Medicine (F.W.G., R.W., S.T.T., C.J.K., J.R.), University of Florida College of Medicine, Jacksonville, Florida; Division of Acute Care Surgery and Surgical Critical Care, Department of Surgery (S.B.), University of Florida College of Medicine Gainesville, Florida; University of Florida College of Medicine (S.S., T.R.), Gainesville; Florida; Department of Emergency Medicine (J.D.K.), State University of New York Downstate, Brooklyn, New York; Division of Cardiology, Department of Internal Medicine (S.D.), University of Florida College of Medicine, Jacksonville, Florida; and Department of Emergency Medicine (A.E.J.), University of Mississippi Medical Center, Jackson, Mississippi.
Abstract
BACKGROUND: Severe sepsis and septic shock mortality has improved; however, rates of persistent (28-90 days) and long-term (>90 day) organ dysfunction in sepsis survivors are unknown. METHODS: Secondary analysis of a prospective cohort of adult emergency department patients with severe sepsis. RESULTS: Of 110 sepsis admissions, we obtained follow-up on 51 of 78 survivors of whom 41% (21 of 51) had persistent organ dysfunction: pulmonary, 18% (9 of 51); renal, 22% (11 of 51); coagulopathy, 10% (5 of 51); cardiovascular, 6% (3 of 51); hepatic, 2% (1 of 51); and neurologic, 3% (3 of 51). We obtained follow-up on 40 of 73 survivors at more than 90 days of whom 38% (15 of 40) had long-term organ dysfunction: pulmonary, 13% (5 of 40); renal, 18% (7 of 40); coagulopathy, 3% (1 of 40); cardiovascular, 5% (2 of 40); hepatic, 0%; and neurologic, 5% (2 of 40). Readmission rate within 90 days was 32% (25 of 78), and recurrent sepsis was the cause of readmission in 52% (13 of 25). Baseline SOFA scores from the index sepsis admission were compared using Wilcoxon rank-sum test and were significantly different in participants with organ dysfunction versus those without organ dysfunction at less than 90 days (z, -2.51; p = 0.01). CONCLUSION: Readmission with recurrent sepsis and organ dysfunction occurs frequently in sepsis survivors. Baseline SOFA score may be predictive of sepsis recidivism and persistent or recurrent organ dysfunction. LEVEL OF EVIDENCE: Prognostic/epidemiologic study, level IV.
BACKGROUND: Severe sepsis and septic shock mortality has improved; however, rates of persistent (28-90 days) and long-term (>90 day) organ dysfunction in sepsis survivors are unknown. METHODS: Secondary analysis of a prospective cohort of adult emergency department patients with severe sepsis. RESULTS: Of 110 sepsis admissions, we obtained follow-up on 51 of 78 survivors of whom 41% (21 of 51) had persistent organ dysfunction: pulmonary, 18% (9 of 51); renal, 22% (11 of 51); coagulopathy, 10% (5 of 51); cardiovascular, 6% (3 of 51); hepatic, 2% (1 of 51); and neurologic, 3% (3 of 51). We obtained follow-up on 40 of 73 survivors at more than 90 days of whom 38% (15 of 40) had long-term organ dysfunction: pulmonary, 13% (5 of 40); renal, 18% (7 of 40); coagulopathy, 3% (1 of 40); cardiovascular, 5% (2 of 40); hepatic, 0%; and neurologic, 5% (2 of 40). Readmission rate within 90 days was 32% (25 of 78), and recurrent sepsis was the cause of readmission in 52% (13 of 25). Baseline SOFA scores from the index sepsis admission were compared using Wilcoxon rank-sum test and were significantly different in participants with organ dysfunction versus those without organ dysfunction at less than 90 days (z, -2.51; p = 0.01). CONCLUSION: Readmission with recurrent sepsis and organ dysfunction occurs frequently in sepsis survivors. Baseline SOFA score may be predictive of sepsis recidivism and persistent or recurrent organ dysfunction. LEVEL OF EVIDENCE: Prognostic/epidemiologic study, level IV.
Authors: Leah K Winer; Nadine Beckmann; Rosalie A Veile; Michael D Goodman; Charles C Caldwell; Vanessa Nomellini Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-03-06 Impact factor: 5.464
Authors: Scott C Brakenridge; Philip A Efron; Michael C Cox; Julie A Stortz; Russell B Hawkins; Gabriela Ghita; Anna Gardner; Alicia M Mohr; Stephen D Anton; Lyle L Moldawer; Frederick A Moore Journal: Ann Surg Date: 2019-09 Impact factor: 12.969
Authors: Philip A Efron; Alicia M Mohr; Azra Bihorac; Hiroyuki Horiguchi; McKenzie K Hollen; Mark S Segal; Henry V Baker; Christiaan Leeuwenburgh; Lyle L Moldawer; Frederick A Moore; Scott C Brakenridge Journal: Surgery Date: 2018-05-26 Impact factor: 3.982
Authors: Faheem W Guirgis; Sunita Dodani; Lyle Moldawer; Christiaan Leeuwenburgh; Jennifer Bowman; Colleen Kalynych; Alan E Jones; Srinivasa T Reddy; Frederick A Moore Journal: Shock Date: 2017-11 Impact factor: 3.454
Authors: Anna K Gardner; Gabriela L Ghita; Zhongkai Wang; Tezcan Ozrazgat-Baslanti; Steven L Raymond; Robert T Mankowski; Babette A Brumback; Philip A Efron; Azra Bihorac; Frederick A Moore; Stephen D Anton; Scott C Brakenridge Journal: Crit Care Med Date: 2019-04 Impact factor: 7.598
Authors: Russell B Hawkins; Julie A Stortz; David C Holden; Zhongkai Wang; Steven L Raymond; Michael C Cox; Scott C Brakenridge; Frederick A Moore; Lyle L Moldawer; Philip A Efron Journal: Surgery Date: 2019-12-31 Impact factor: 3.982
Authors: Faheem W Guirgis; Michael A Puskarich; Carmen Smotherman; Sarah A Sterling; Shiva Gautam; Frederick A Moore; Alan E Jones Journal: J Intensive Care Med Date: 2017-11-15 Impact factor: 3.510
Authors: Faheem W Guirgis; Christiaan Leeuwenburgh; Lyle Moldawer; Gabriela Ghita; Lauren Page Black; Morgan Henson; Elizabeth DeVos; David Holden; Phil Efron; Srinivasa T Reddy; Frederick A Moore Journal: Ann Intensive Care Date: 2021-05-20 Impact factor: 6.925